Tejnaksh Healthcare Ltd
Tejnaksh Healthcare Limited is engaged in the business of providing hospital and healthcare services in Maharashtra with focus on clinical services, diagnostic facilities, and research. [1]
- Market Cap ₹ 121 Cr.
- Current Price ₹ 119
- High / Low ₹ 194 / 107
- Stock P/E 55.2
- Book Value ₹ 20.4
- Dividend Yield 0.00 %
- ROCE 16.0 %
- ROE 13.9 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 4.45% over past five years.
- Company has a low return on equity of 13.4% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.36 | 1.30 | 1.14 | 1.44 | 2.01 | 4.75 | 6.53 | 8.62 | 13.96 | 11.50 | 8.56 | 8.12 | 7.74 | |
| 0.79 | 0.78 | 0.55 | 0.49 | 1.04 | 2.45 | 3.67 | 4.37 | 10.34 | 7.93 | 4.96 | 3.77 | 3.71 | |
| Operating Profit | 0.57 | 0.52 | 0.59 | 0.95 | 0.97 | 2.30 | 2.86 | 4.25 | 3.62 | 3.57 | 3.60 | 4.35 | 4.03 |
| OPM % | 41.91% | 40.00% | 51.75% | 65.97% | 48.26% | 48.42% | 43.80% | 49.30% | 25.93% | 31.04% | 42.06% | 53.57% | 52.07% |
| 0.02 | 0.02 | -0.00 | 0.01 | 0.04 | 0.03 | 0.20 | 0.43 | 1.42 | 0.48 | 0.14 | 0.08 | 0.18 | |
| Interest | 0.01 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 0.19 | 0.96 | 0.77 | 0.80 | 0.54 | 0.47 | 0.58 |
| Depreciation | 0.08 | 0.10 | 0.11 | 0.11 | 0.14 | 0.21 | 0.34 | 0.44 | 0.52 | 0.59 | 0.61 | 0.59 | 0.70 |
| Profit before tax | 0.50 | 0.43 | 0.48 | 0.85 | 0.87 | 2.12 | 2.53 | 3.28 | 3.75 | 2.66 | 2.59 | 3.37 | 2.93 |
| Tax % | 32.00% | 32.56% | 35.42% | 32.94% | 32.18% | 37.74% | 33.20% | 26.22% | 28.27% | 27.44% | 22.39% | 25.22% | |
| Net Profit | 0.34 | 0.30 | 0.31 | 0.57 | 0.60 | 1.32 | 1.69 | 2.43 | 2.69 | 1.92 | 2.00 | 2.52 | 2.19 |
| EPS in Rs | 0.81 | 1.29 | 1.66 | 2.38 | 2.65 | 1.89 | 1.97 | 2.48 | 2.15 | ||||
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 4% |
| 3 Years: | -17% |
| TTM: | -15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 9% |
| 3 Years: | -2% |
| TTM: | -19% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 26% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 17% |
| 3 Years: | 13% |
| Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.01 | 0.01 | 0.01 | 0.80 | 1.10 | 2.21 | 2.21 | 10.16 | 10.16 | 10.16 | 10.16 | 10.16 | |
| Reserves | 0.70 | 1.00 | 1.31 | 1.88 | 1.69 | 5.14 | 5.73 | 8.19 | 2.93 | 4.85 | 6.87 | 9.40 | 10.55 |
| 0.37 | 0.37 | 0.36 | 0.47 | -0.00 | -0.00 | 6.39 | 7.64 | 6.33 | 7.25 | 4.93 | 7.03 | 6.15 | |
| 0.54 | 0.30 | 0.33 | 0.62 | 1.04 | 0.60 | 0.55 | 1.13 | 1.99 | 2.02 | 1.92 | 2.09 | 2.96 | |
| Total Liabilities | 1.62 | 1.68 | 2.01 | 2.98 | 3.53 | 6.84 | 14.88 | 19.17 | 21.41 | 24.28 | 23.88 | 28.68 | 29.82 |
| 1.19 | 1.40 | 1.37 | 1.43 | 2.86 | 3.34 | 13.43 | 14.54 | 16.19 | 16.59 | 14.34 | 14.55 | 23.56 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 | -0.00 | -0.00 | -0.00 | 0.39 | 0.65 | 0.79 | 8.89 | 0.04 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 | 2.59 | 0.07 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 | 1.06 |
| 0.43 | 0.28 | 0.64 | 1.55 | 0.65 | 0.91 | 1.38 | 3.57 | 3.77 | 5.98 | 7.69 | 4.18 | 5.16 | |
| Total Assets | 1.62 | 1.68 | 2.01 | 2.98 | 3.53 | 6.84 | 14.88 | 19.17 | 21.41 | 24.28 | 23.88 | 28.68 | 29.82 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.62 | 0.09 | 0.11 | 0.08 | 1.71 | 3.67 | 1.78 | 3.88 | 3.15 | 1.00 | 0.84 | 9.13 | |
| -0.36 | -0.31 | -0.08 | -0.17 | -1.59 | -3.26 | -7.91 | -2.59 | -1.49 | -1.16 | 1.56 | -10.40 | |
| -0.05 | -0.00 | -0.01 | 0.11 | -0.04 | -0.13 | 6.39 | -0.64 | -2.08 | 0.22 | -2.86 | 1.61 | |
| Net Cash Flow | 0.21 | -0.22 | 0.02 | 0.02 | 0.08 | 0.29 | 0.26 | 0.64 | -0.42 | 0.06 | -0.47 | 0.35 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 5.75 | 16.82 | 15.78 | 20.23 |
| Inventory Days | 98.06 | 86.45 | 126.74 | 182.50 | 340.67 | 251.90 | ||||||
| Days Payable | 114.40 | 134.47 | 177.43 | 143.79 | 129.78 | 77.11 | ||||||
| Cash Conversion Cycle | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -16.34 | -48.03 | -50.69 | 5.75 | 55.53 | 226.67 | 195.02 |
| Working Capital Days | -96.62 | -2.81 | 102.46 | 240.80 | -5.45 | -1.54 | 19.56 | -5.93 | 24.58 | 105.37 | 9.81 | -13.93 |
| ROCE % | 54.84% | 35.77% | 31.37% | 42.08% | 36.29% | 48.57% | 26.45% | 26.20% | 24.13% | 16.60% | 14.20% | 16.02% |
Documents
Announcements
- Announcement Under Regulation 30 In Relation To Company Has Launched New Product Andro-Sim. 21 Nov
- Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulation 2015. 19 Nov
- Announcement Under Regulation 30 In Relation To Managing Director Of Our Company Has Started 'Think Tank Arena For Innovations' Session 14 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Nov - In compliance of provision of Regulation 47 read with Regulation 33 of the SEBI (LODR) Regulations, 2015, the Company has published the Un-Audited Financial Results …
- Announcement Under Regulation 30 In Relation To Company Has Attended Joint Andrology Workshop And World Congress JAWS 2022 At New Delhi 7 Nov
Annual reports
Concalls
-
Feb 2018TranscriptPPT
Services
Super Speciality Hospital: The Co runs the Institute of Urology, Dhule a super speciality hospital that provides a comprehensive range of services from consultations and investigation to treatment of various urological problems such as kidneys, ureter, bladder, prostate, and other genital organs. It provides Laser Prostatectomy, Endourology & LASER Treatment, Dialysis Unit, Clinical Nephrology etc.
Healthcare Equipments: The Co also sells Healthcare Equipments including Radiation Free PERC Simulator, PCNL Logic Simulator, Fluoroscopy Guided Simulator, Stone Manipulation Simulator etc.
Education Institute: The Co also operates its coaching facility in Dhule. The academy aims to coach 10+2, XI and XII students for NEET, AIPMT, JEE and allied entrances. [1]